NCT07386210 is a NA clinical trial of Rosemary extract infusion in Hypertension Arterial, sponsored by awatef Sassi.

Who is sponsoring NCT07386210?

NCT07386210 is sponsored by awatef Sassi.

What drugs are being tested in NCT07386210?

Interventions in NCT07386210: Rosemary extract infusion, Placebo.

What condition does NCT07386210 study?

NCT07386210 studies Hypertension Arterial.

Is NCT07386210 still recruiting?

NCT07386210 is currently completed. Last updated 4 February 2026.

Last reviewed 2026-02-04 · How we verify

NCT07386210

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antihypertensive Effects of Rosmarinus Officinalis L. Infusion

Completed NA Last updated 4 February 2026

What this trial tests

NA trial testing Rosemary extract infusion in Hypertension Arterial in 54 participants. Completed in 29 August 2025.

Timeline

20 March 2023

Primary endpoint
28 August 2025

29 August 2025

Quick facts

Lead sponsor	awatef Sassi
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	54
Start date	20 March 2023
Primary completion	28 August 2025
Estimated completion	29 August 2025
Sites	2 locations across Tunisia

Drugs / interventions tested

Rosemary extract infusion
Placebo

Conditions studied

Hypertension Arterial — all drugs for Hypertension Arterial →

Sponsor

awatef Sassi

Who can join

Adults 18 to 65, male only, with Hypertension Arterial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study assessed the antihypertensive effect of rosemary tea through a placebo-controlled clinical study, angiotensin-converting enzyme (ACE) inhibition analysis, and in silico evaluation of interactions between rosemary bioactive compounds and the AT1R (Angiotensin II Type 1 Receptor). A randomized, double-blind, placebo-controlled trial was conducted in 54 male patients with mild hypertension. Participants were assigned to receive either rosemary infusion (n = 27) or placebo (n = 23) for 45 days. Ambulatory blood pressure monitoring wass used to evaluate blood pressure parameters. Serum ACE activity was measured at baseline and after the intervention using FAPGG hydrolysis. Molecular docking simulations were performed using the Dock 4.2 software.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypertension Arterial

Currently open trials in the same condition.

NCT05942729 — Etiological DiagnOsis of caRdiac Diseases Based on echoCardiograpHIc Images and Clinical Data. · recruiting

Other awatef Sassi trials

Trials by the same sponsor.

NCT07352124 — Rosemary Infusion for Hypertension With Hypertriglyceridemia · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07386210 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by awatef Sassi
Last refreshed: 4 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07386210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing